CTLA4 and neoplasm: Treatment using a PARP inhibitor together with immunotherapy of CTLA-4 blockade was shown to induce long-term survival in a BRCA1-deficient ovarian tumor model, with local induction of antitumor immunity and the production of increased levels of interferon-g (IFNγ) in the peritoneal tumor environment.